3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx (formerly Kilpest India) held its 53rd AGM on September 26, 2025 via video conferencing, chaired by CMD Dhirendra Dubey. Shareholders approved all 10 resolutions, including the FY25 financial statements, a Rs. 4 per share dividend, re-appointment of the CMD for five years, and revision in remuneration for the CMD and CFO. The company's consolidated FY25 performance was strong, with revenue of Rs. 96.47 crore, profit after tax of Rs. 47.69 crore, and EPS of Rs. 55.66. Management also highlighted the recently completed acquisition of Belgium-based Coris BioConcept for a total consideration of £2.77 million, and export sales nearly doubling to Rs. 171 million in FY25. The company's molecular diagnostics products are now present in over 70 countries, and it holds a 12-15% share of India's Rs. 350-450 crore molecular diagnostics market, with guided growth of 15-20% for FY26.
Smooth approval of all resolutions signals stable governance and continuity in leadership. Strong FY25 results, a healthy dividend payout, and the completed Coris acquisition support the growth story, though investors should track integration of the Belgium business and rising competition in India's molecular diagnostics space.